PeptiSystems and CordenPharma enter collaboration to evaluate new-generation peptide synthesis technology
PeptiSystems, announces that an agreement has been signed with CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging.
Under the terms of this agreement, CordenPharma will evaluate a new synthesis instrument, PeptiPilot®, developed by PeptiSystems. It is based on flow-through column technology. This technology can be used for process development and large-scale commercial manufacturing of peptides in non-GMP and GMP quality. PeptiSystems’ flow-through column technology enables in-line continuous monitoring of the synthesis to increase synthesis control, automation, and productivity while maintaining the same or higher purity and yield compared to current technologies. In comparison, PeptiSystems technology will decrease the overall time needed for large-scale peptide synthesis by 50-90%, saving both on costs and production time in the factory.
The technology has also demonstrated a reduction in solvent waste generated by 40-50%. Since solvents represent the vast majority of the waste generated in chemical processes in solid phase synthesis of peptides, this represents a major reduction in the carbon footprint and a step towards a greener manufacturing process.
Dr. Matthieu Giraud, Director, Global Peptide, Lipids, and Carbohydrates Platforms at CordenPharma International, comments, “We are pleased to work with PeptiSystems as we work on innovative and sustainable ways to match the continued strong demand for peptide-based pharmaceuticals while reducing our carbon footprint.”
Lars Holmberg, PeptiSystems’ CEO comments, “We are thrilled that CordenPharma has decided to work with PeptiSystems to evaluate our technology. Corden Pharma’s expertise and feedback is very valuable for us in the continued development of these instruments and in our mission towards greener and more efficient peptide manufacturing.”